Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Prevention Trial of Canakinumab in High-Risk Subjects for Lung Cancer
2020-002773-10Phase 3Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchial carcinoma comparing Canakinumab with Placebo (2 arms). Primary endpoint: Time To Lung Cancer (TTLC). Started Sep 2021; status: terminated.
02
Drugs
canakinumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on 2020-002773-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002773-10.